Literature DB >> 30907889

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats.

Michael G Katz1, Anthony S Fargnoli1, Sarah M Gubara1, Malik Bisserier1, Yassine Sassi1, Charles R Bridges1, Roger J Hajjar1, Lahouaria Hadri2.   

Abstract

In this protocol, we detail the correct procedural steps and necessary precautions to successfully perform a left pneumonectomy and induce PAH in rats with the additional administration of monocrotaline (MCT) or SU5416 (Sugen). We also compare these two models to other PAH models commonly used in research. In the last few years, the focus of animal PAH models has moved towards studying the mechanism of angioproliferation of plexiform lesions, in which the role of increased pulmonary blood flow is considered as an important trigger in the development of severe pulmonary vascular remodeling. One of the most promising rodent models of increased pulmonary flow is the unilateral left pneumonectomy combined with a "second hit" of MCT or Sugen. The removal of the left lung leads to increased and turbulent pulmonary blood flow and vascular remodeling. Currently, there is no detailed procedure of the pneumonectomy surgery in rats. This article details a step-by-step protocol of the pneumonectomy surgical procedure and post-operative care in male Sprague-Dawley rats. Briefly, the animal is anesthetized and the chest is opened. Once the left pulmonary artery, pulmonary vein, and bronchus are visualized, they are ligated and the left lung is removed. The chest then closed and the animal recovered. Blood is forced to circulate only on the right lung. This increased vascular pressure leads to a progressive remodeling and occlusion of small pulmonary arteries. The second hit of MCT or Sugen is used one week post-surgery to induce endothelial dysfunction. The combination of increased blood flow in the lung and endothelial dysfunction produces severe PAH. The primary limitation of this procedure is that it requires general surgical skills.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30907889      PMCID: PMC7992111          DOI: 10.3791/59050

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  13 in total

Review 1.  The monocrotaline model of pulmonary hypertension in perspective.

Authors:  Jose G Gomez-Arroyo; Laszlo Farkas; Aysar A Alhussaini; Daniela Farkas; Donatas Kraskauskas; Norbert F Voelkel; Harm J Bogaard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-30       Impact factor: 5.464

2.  The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally.

Authors:  Edwina Cahill; Simon C Rowan; Michelle Sands; Mark Banahan; Donal Ryan; Katherine Howell; Paul McLoughlin
Journal:  Exp Physiol       Date:  2012-02-24       Impact factor: 2.969

3.  Effect of a surgical aortocaval fistula on monocrotaline-induced pulmonary hypertension.

Authors:  Toshihiko Nishimura; John L Faul; Gerald J Berry; Peter N Kao; Ronald G Pearl
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

4.  Ventricular and pulmonary vascular remodeling induced by pulmonary overflow in a chronic model of pretricuspid shunt.

Authors:  Daniele Linardi; Alessio Rungatscher; Mohammed Morjan; Paolo Marino; Giovanni Battista Luciani; Alessandro Mazzucco; Giuseppe Faggian
Journal:  J Thorac Cardiovasc Surg       Date:  2014-05-05       Impact factor: 5.209

5.  The role of increased pulmonary blood flow in pulmonary arterial hypertension.

Authors:  M E van Albada; R G Schoemaker; M S Kemna; A H Cromme-Dijkhuis; R van Veghel; R M F Berger
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

Review 6.  The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models.

Authors:  Michael G Dickinson; Beatrijs Bartelds; Marinus A J Borgdorff; Rolf M F Berger
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-26       Impact factor: 5.464

7.  Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats.

Authors:  C M Happé; M A de Raaf; N Rol; I Schalij; A Vonk-Noordegraaf; N Westerhof; N F Voelkel; F S de Man; H J Bogaard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-04-01       Impact factor: 5.464

8.  Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension.

Authors:  R James White; David F Meoli; Robert F Swarthout; Dara Y Kallop; Irfan I Galaria; Jennifer L Harvey; Christine M Miller; Burns C Blaxall; Carla M Hall; Richard A Pierce; Carlyne D Cool; Mark B Taubman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-06-22       Impact factor: 5.464

Review 9.  Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

Authors:  Kurt R Stenmark; Barbara Meyrick; Nazzareno Galie; Wolter J Mooi; Ivan F McMurtry
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-09-11       Impact factor: 5.464

Review 10.  Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

Authors:  Jane A Leopold; Bradley A Maron
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

View more
  5 in total

1.  Right predominant electrical remodeling in a pure model of pulmonary hypertension promotes reentrant arrhythmias.

Authors:  Benjamin Strauss; Malik Bisserier; Emerson Obus; Michael G Katz; Anthony Fargnoli; Marine Cacheux; Joseph G Akar; James P Hummel; Lahouaria Hadri; Yassine Sassi; Fadi G Akar
Journal:  Heart Rhythm       Date:  2021-09-23       Impact factor: 6.779

2.  Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.

Authors:  Malik Bisserier; Michael G Katz; Carlos Bueno-Beti; Agnieszka Brojakowska; Shihong Zhang; Sarah Gubara; Erik Kohlbrenner; Shahood Fazal; Anthony Fargnoli; Peter Dorfmuller; Marc Humbert; Akiko Hata; David A Goukassian; Yassine Sassi; Lahouaria Hadri
Journal:  Int J Mol Sci       Date:  2021-08-24       Impact factor: 6.208

3.  Experimental animal models of pulmonary hypertension: Development and challenges.

Authors:  Xiao-Han Wu; Jie-Ling Ma; Dong Ding; Yue-Jiao Ma; Yun-Peng Wei; Zhi-Cheng Jing
Journal:  Animal Model Exp Med       Date:  2022-03-25

Review 4.  Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases.

Authors:  Malik Bisserier; Xiao-Qing Sun; Shahood Fazal; Irene C Turnbull; Sébastien Bonnet; Lahouaria Hadri
Journal:  Cells       Date:  2022-03-12       Impact factor: 7.666

5.  Plexiform Lesions in Pulmonary Arterial Hypertension: Are we Getting Closer to Manage with More Patience and Rigor?

Authors:  Hugo Hyung Bok Yoo
Journal:  Arq Bras Cardiol       Date:  2020-09       Impact factor: 2.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.